Athersys, Inc. is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company's MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients. In the neurological area, the Company evaluated in a completed Phase II trial, the potential for MultiStem treatment of patients with a history of neurological damage from an ischemic stroke. The Company initiated a Phase II clinical study in the United States for the administration of MultiStem cell therapy to patients with a history of an acute myocardial infarction, or AMI.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: ATHX
- Previous Close: $1.18
- 50 Day Moving Average: $1.29
- 200 Day Moving Average: $1.70
- 52-Week Range: $1.02 - $2.90
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.00
- P/E Growth: -0.23
- Market Cap: $101.74M
- Outstanding Shares: 85,498,000
- Beta: -0.17
- Net Margins: -17.12%
- Return on Equity: -22.82%
- Return on Assets: -16.90%
Companies Related to Athersys:
- Current Ratio: 3.98%
- Quick Ratio: 3.98%
What is Athersys' stock symbol?
Athersys trades on the NASDAQ under the ticker symbol "ATHX."
Where is Athersys' stock going? Where will Athersys' stock price be in 2017?
2 equities research analysts have issued 1 year target prices for Athersys' stock. Their forecasts range from $7.00 to $10.00. On average, they expect Athersys' share price to reach $8.50 in the next twelve months.
When will Athersys announce their earnings?
Athersys is scheduled to release their next quarterly earnings announcement on Wednesday, March, 8th 2017.
What are analysts saying about Athersys stock?
Here are some recent quotes from research analysts about Athersys stock:
- Needham & Company LLC analysts commented, "Athersys is developing MultiStem, an off-the-shelf cell therapy that promotes tissue repair. The lead indication is ischemic stroke. Existing stroke treatments, which focus on removing the offending blood clot, can only be used in a short window of time, but MultiStem has shown efficacy in a longer time window (24-36 hours) and can thus address far more patients. Athersys' Japanese partner Healios will start a 220-patient pivotal trial shortly. Data is expected in mid-2018. While there is some controversy around the Phase II data, we believe the trial has a favorable risk:reward in what we see as a blockbuster opportunity. Initiate at Buy with a $7 price target." (2/7/2017)
According to Zacks Investment Research, "Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The company's lead product candidate, ATHX-105, is an oral, selective 5HT2c receptor agonist in Phase I clinical trials for the treatment of obesity. The company is also developing other orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders, utilizing proprietary technologies, including Random Activation of Gene Expression (RAGE). Athersys is developing MultiStem(r), its patented, adult-derived ``off the shelf'' stem cell product platform, for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation/oncology support, ischemic stroke and other indications. " (11/14/2016)
Maxim Group analysts commented, "On September 9, Sorrento presented at an industry conference in New York City. We had an additional meeting with CFO Kevin Herde." (9/12/2016)
Who owns Athersys stock?
Athersys' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Prudential PLC (2.51%), State Street Corp (1.31%), Russell Investments Group Ltd. (0.48%), Ladenburg Thalmann Financial Services Inc. (0.16%) and Oxford Asset Management (0.08%). Company insiders that own Athersys stock include Bokkelen Gil Van, Ismail Kola, John J Harrington, Kenneth H Traub, Laura K Campbell, Robert J Deans, William Lehmann Jr and William Lehmann, Jr.
Who sold Athersys stock? Who is selling Athersys stock?
Athersys' stock was sold by a variety of institutional investors in the last quarter, including Ladenburg Thalmann Financial Services Inc.. Company insiders that have sold Athersys stock in the last year include John J Harrington and William Lehmann Jr.
Who bought Athersys stock? Who is buying Athersys stock?
Athersys' stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Prudential PLC, Oxford Asset Management and State Street Corp. Company insiders that have bought Athersys stock in the last two years include Ismail Kola, Kenneth H Traub and Laura K Campbell.
How do I buy Athersys stock?
Shares of Athersys can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Athersys stock cost?
One share of Athersys stock can currently be purchased for approximately $1.20.